Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD

CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807
Source: Journal of Opioid Management - Category: Addiction Authors: Source Type: research